研究西达本胺(Chidamide)对结肠癌细胞系HCT-15的增殖抑制作用及机制. 以不同浓度西达本胺处理HCT-15细胞,CCK-8法检测细胞增殖情况及细胞的药物敏感性;平板克隆形成实验检测细胞体外克隆形成能力;流式细胞术检测细胞凋亡;EdU实验检测细胞增殖周期;Western blot检测乙酰化组蛋白、线粒体凋亡途径相关蛋白、细胞周期相关蛋白表达水平的变化. 结果表明:西达本胺抑制HCT-15细胞增殖呈浓度和时间依赖性,细胞体外克隆形成能力减弱,凋亡增多,细胞分裂相明显减少、总周期变慢,乙酰化组蛋白H3和H4、线粒体介导的相关凋亡蛋白表达上调、p21、p27表达上调、CDK2、CyclinA2蛋白表达下调. 西达本胺可抑制HCT-15细胞增殖,通过线粒体途径诱导细胞凋亡并阻滞细胞周期.
The inhibitory effect and mechanism of Chidamide on the proliferation of colon cancer cell line HCT-15 were studied. HCT-15 were treated with different concentrations of Chidamide, and cell proliferation and drug sensitivity were detected by CCK-8 method; The ability of cell clone formation in vitro was detected by plate clone formation assay. Apoptosis was detected by flow cytometry. The cell cycle was detected by EdU experiment, the expression level of acetylated histone, mitochondrial apoptosis-related proteins, and cell cycle-related proteins were detected by Western blot. The results show that Chidamide inhibited the proliferation of HCT-15 cells in a concentration and time-dependent manner, weakened the ability- DOI:10.3969/j.issn.1000-1565.2022.02.009西达本胺通过线粒体凋亡途径诱导结肠癌HCT-15细胞凋亡赵琳珊1,2,李玉苗1,李楠1,贾友超1,王晓芳1,韩强1,臧爱民1(1.河北大学附属医院 肿瘤内科,河北省肿瘤放化疗机制与规程研究重点实验室,河北 保定 071000;2.河北大学 临床医学院,河北 保定 071000)摘 要:研究西达本胺(Chidamide)对结肠癌细胞系HCT-15的增殖抑制作用及机制. 以不同浓度西达本胺处理HCT-15细胞,CCK-8法检测细胞增殖情况及细胞的药物敏感性;平板克隆形成实验检测细胞体外克隆形成能力;流式细胞术检测细胞凋亡;EdU实验检测细胞增殖周期;Western blot检测乙酰化组蛋白、线粒体凋亡途径相关蛋白、细胞周期相关蛋白表达水平的变化. 结果表明:西达本胺抑制HCT-15细胞增殖呈浓度和时间依赖性,细胞体外克隆形成能力减弱,凋亡增多,细胞分裂相明显减少、总周期变慢,乙酰化组蛋白H3和H4、线粒体介导的相关凋亡蛋白表达上调、p21、p27表达上调、CDK2、CyclinA2蛋白表达下调. 西达本胺可抑制HCT-15细胞增殖,通过线粒体途径诱导细胞凋亡并阻滞细胞周期. 关键词:西达本胺;结肠癌;乙酰化;线粒体凋亡途径中图分类号:R917 文献标志码:A 文章编号:1000-1565(2022)02-0164-07Chidamide induces apoptosis of colon cancer HCT-15 cells through mitochondrial apoptosis pathwayZHAO Linshan1,2, LI Yumiao1, LI Nan1, JIA Youchao1, WANG Xiaofang1, HAN Qiang1, ZANG Aimin1(1. Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding 071000, China; 2. Clinical Medical College, Hebei University, Baoding 071000, China )Abstract: The inhibitory effect and mechanism of Chidamide on the proliferation of colon cancer cell line HCT-15 were studied. HCT-15 were treated with different concentrations of Chidamide, and cell proliferation and drug sensitivity were detected by CCK-8 method; The ability of cell clone formation in vitro was detected by plate clone formation assay. Apoptosis was detected by flow cytometry. The cell cycle was detected by EdU experiment, the expression level of acetylated histone, mitochondrial apoptosis-related proteins, and cell cycle-related proteins were detected by Western blot. The results show that Chidamide inhibited the proliferation of HCT-15 cells in a concentration and time-dependent manner, weakened the ability- 收稿日期:2021-11-19 基金项目:河北省政府资助临床医学优秀人才课题(361007);河北大学医学学科培育项目(2021B15) 第一作者:赵琳珊(1995—),女,河南安阳人,河北大学在读硕士研究生,主要从事肿瘤药理学研究. E-mail:13502155703@163.com 通信作者:臧爱民(1962—),女,河北保定人,河北大学附属医院教授,主要从事肿瘤生物学治疗方向研究. E-mail:booszam@sina.com韩强(1968—),女,河北保定人,河北大学附属医院主任医师,主要从事肿瘤生物学治疗方向研究. E-mail:hanqiang68716@alliyun.com第2期赵琳珊等:西达本胺通过线粒体凋亡途径诱导结肠癌HCT-15细胞凋亡of cell cloning in vitro, increased apoptosis, significantly reduced the image of cell division, and slowed down the total cycle. The results of western blot showed that acetylated histones H3, H4, mitochondria-mediated apoptosis-related proteins, p21, and p27 were up-regulated. Meanwhile, CDK2 and cyclin A2 were down-regulated. Chidamide could inhibit proliferation, induce apoptosis and block the cell cycle of HCT-15 cells.
[1] 中国结直肠癌诊疗规范(2020年版)专家组.国家卫生健康委员会中国结直肠癌诊疗规范(2020年版)[J].中华胃肠外科杂志,2020,23(6):521-539. DOI:10.3760/cma.j.cn115610-20200504-00348.
[2] GRAHAM J S, KAYE S B, BROWN R. The promises and pitfalls of epigenetic therapies in solid tumours[J]. European Journal of Cancer, 2009, 45(7):1129-1136. DOI:10.1016/j.ejca.2009.01.003.
[3] JIANG Z F, LI W, HU X C, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer(ACE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20: 806-815. DOI:10.1016/S1470-2045(19)30164-0.
[4] DICKINSON M, JOHNSTONE R W, PRINCE H M. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect[J]. Investigational New Drugs, 2010, 28(1):3-20. DOI:10.1007/s10637-010-9596-y.
[5] ZHANG Q Y, WANG T, GENG C Z, et al. Exploratory clinical study of Chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer [J]. Chin J Cancer Res, 2018, 30: 605-612.DOI:10.21147/j.issn.1000-9604.2018.06.05.
[6] ZHANG N N, LIANG C X, SONG W Y, et al. Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC[J]. J Cancer, 2019, 10: 1275-1287. DOI:10.7150/jca.28570.
[7] YUAN X G,HUANG Y R,YU T, et al. Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspasedependent manner.[J].Oncol Lett, 2019, 18: 411-419. DOI:10.3892/ol.2019.10301.
[8] DAWSON M, KOUZARIDES T. Cancer epigenetics: from mechanism to therapy[J]. Cell, 2012, 150(1):12-27. DOI:10.1016/j.cell.2012.06.013.
[9] FRANKLIN, JAMES L. Redox regulation of the intrinsic pathway in neuronal apoptosis[J]. Antioxidants & Redox Signaling, 2011, 14(8):1437-1448. DOI:10.1089/ars.2010.3596.
[10] KINNALLY K W, ANTONSSON B. A tale of two mitochondrial channels, MAC and PTP, in apoptosis[J]. Apoptosis, 2007, 12(5):857-868. DOI:10.1007/s10495-007-0722-z.
[11] LIN L M,QUE Y M,LU P F, et al. Chidamide inhibits acute myeloid leukemia cell proliferation by incRNA VPS9D1-AS1 downregulation via MEK/ERK signaling pathway[J].Front Pharmacol, 2020, 11: 569651. DOI:10.3389/fphar.2020.569651.
[12] CAO L X, ZHAO S R, YANG Q X, et al. Chidamide combined with doxorubicin induced p53-driven cell cycle arrest and cell apoptosis reverse multidrug resistance of breast cancer [J]. Front Oncol, 2021, 11: 614458. DOI:10.3389/fonc.2021.614458.
[13] PENG J,LI S J,FU X, et al. Chidamide acts on the histone deacetylase-mediated miR-34a/Bcl-2 axis to regulate NB4 cell line proliferation and apoptosis[J].Kaohsiung J Med Sci, 2020, 36: 1004-1013. DOI:10.1002/kjm2.12283.
[14] SHI P C, ZHANG L S, CHEN K, et al. Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially for p16-deleted patients through DNA damage[J]. Pharmacogenomics, 2017, 18: 1259-1270. DOI:10.2217/pgs-2017-0061.
[15] LIU L, QIU S, LIU Y, et al. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice[J]. Neoplasma, 2016, 63: 193-200. DOI:10.4149/203_150422N214.
[16] ZHOU J N, ZHANG C J, SUI X X, et al. Histone deacetylase inhibitor Chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway[J]. Invest New Drugs, 2018, 36: 571-580. DOI:10.1007/s10637-017-0552-y. (
